Analysts Forecast 17% Growth Potential for ESML
ETF Analyst Target Price: The iShares ESG Aware MSCI USA Small-Cap ETF (ESML) has an implied analyst target price of $50.03, indicating a potential upside of 16.59% from its current trading price of $42.91.
Notable Holdings with Upside: Key underlying holdings in ESML include MoonLake Immunotherapeutics (MLTX), The RealReal Inc (REAL), and Avadel Pharmaceuticals PLC (AVDL), all showing significant upside potential based on analyst target prices.
Price Comparisons: MLTX is currently priced at $54.17 with a target of $76.80 (41.78% upside), REAL at $7.62 with a target of $10.08 (32.32% upside), and AVDL at $14.82 with a target of $18.00 (21.46% upside).
Investor Considerations: Questions arise regarding the validity of analysts' targets, whether they are justified or overly optimistic, and the need for further investor research into recent company and industry developments.
Trade with 70% Backtested Accuracy
Analyst Views on ESML

No data
About the author

52-Week Range of ESML: ESML's share price has a 52-week low of $32.905 and a high of $46.54, with the last trade recorded at $45.90.
200-Day Moving Average: The article suggests that comparing the current share price to the 200-day moving average can be a useful technical analysis tool.
ETFs Trading Mechanism: Exchange traded funds (ETFs) function similarly to stocks, where investors buy and sell "units" that can be created or destroyed based on demand.
Monitoring ETF Flows: Weekly monitoring of changes in shares outstanding helps identify ETFs with significant inflows or outflows, which can affect the underlying holdings.
ETF Performance Overview: The iShares ESG Aware MSCI USA Small-Cap ETF (ESML) has an implied analyst target price of $53.56, indicating an 18.13% upside from its current trading price of $45.34.
Notable Holdings with Upside: Key underlying holdings of ESML, such as Burford Capital (BUR), MannKind Corp (MNKD), and Liberty Latin America (LILA), show significant potential for price increases based on analyst targets, with upside estimates of 114.68%, 91.42%, and 26.42%, respectively.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets relative to current prices could lead to potential downgrades if not supported by recent developments.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analyst targets and to consider recent company and industry developments that may impact stock performance.
ETF Analyst Target Price: The iShares ESG Aware MSCI USA Small-Cap ETF (ESML) has an implied analyst target price of $51.84, indicating a potential upside of 14.35% from its current trading price of $45.34.
Notable Holdings with Upside: Key underlying holdings of ESML, such as Burford Capital (BUR), BKV Corp (BKV), and WisdomTree Inc (WT), show significant upside potential based on analyst target prices, with BUR having a target 70.56% higher than its current price.
ETF Analyst Target Price: The iShares ESG Aware MSCI USA Small-Cap ETF (ESML) has an implied analyst target price of $51.20, indicating a potential upside of 12.71% from its current trading price of $45.43.
Notable Holdings with Upside: Key underlying holdings of ESML, such as AeroVironment (AVAV), ThredUp (TDUP), and Horizon Bancorp (HBNC), show significant upside potential, with target prices exceeding their recent trading prices by 22.96%, 19.05%, and 18.08%, respectively.
ETF Analysis Overview
- Implied Analyst Target Price for ESML: The iShares ESG Aware MSCI USA Small-Cap ETF (ESML) has an implied analyst target price of $50.67 per unit, based on its underlying holdings.
- Current Trading Price and Upside Potential: With ESML currently trading at approximately $44.32 per unit, analysts project a potential upside of 14.34% based on the average target prices of the ETF's holdings.
Notable Holdings with Upside Potential
- NovoCure Ltd (NVCR): Trading at $12.33 per share, NVCR has an average analyst target price of $27.19, indicating a significant upside of 120.49%.
- Arcutis Biotherapeutics Inc (ARQT): Currently priced at $15.52, ARQT has a target price of $22.62, suggesting a potential increase of 45.78%.
- fuboTV Inc (FUBO): With a recent trading price of $3.54, FUBO's average target price is $5.08, reflecting an upside of 43.79%.
Analyst Target Price Considerations
- Market Sentiment and Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, considering recent developments in the companies and their industries.
- Implications of High Price Targets: A high target price relative to a stock's current trading price may indicate optimism but could also lead to potential downgrades if the targets are based on outdated information.
Conclusion
- Investor Research Importance: The analysis emphasizes the need for further research by investors to assess the validity of analyst targets and the potential for future stock performance.
ETF Analyst Target Price: The iShares ESG Aware MSCI USA Small-Cap ETF (ESML) has an implied analyst target price of $50.03, indicating a potential upside of 16.59% from its current trading price of $42.91.
Notable Holdings with Upside: Key underlying holdings in ESML include MoonLake Immunotherapeutics (MLTX), The RealReal Inc (REAL), and Avadel Pharmaceuticals PLC (AVDL), all showing significant upside potential based on analyst target prices.
Price Comparisons: MLTX is currently priced at $54.17 with a target of $76.80 (41.78% upside), REAL at $7.62 with a target of $10.08 (32.32% upside), and AVDL at $14.82 with a target of $18.00 (21.46% upside).
Investor Considerations: Questions arise regarding the validity of analysts' targets, whether they are justified or overly optimistic, and the need for further investor research into recent company and industry developments.











